US7560107B2
(en)
|
1996-06-26 |
2009-07-14 |
Emory University |
Modified factor VIII
|
AU2002248329B2
(en)
*
|
2001-01-12 |
2007-06-28 |
The American National Red Cross |
Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
|
ATE417618T1
(de)
*
|
2001-10-05 |
2009-01-15 |
Expression Therapeutics Llc |
Faktor-viii-polypeptide auf hohem expressionsniveau codierende nukleinsäure- und aminosäuresequenzen und verwendungsverfahren
|
MXPA04005079A
(es)
*
|
2001-11-30 |
2004-08-19 |
Univ Emory |
Variantes del dominio c2 del factor viii.
|
GB0207092D0
(en)
|
2002-03-26 |
2002-05-08 |
Sod Conseils Rech Applic |
Stable pharmaceutical composition containing factor VIII
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
US7485291B2
(en)
*
|
2003-06-03 |
2009-02-03 |
Cell Genesys, Inc. |
Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
|
WO2005017149A1
(en)
*
|
2003-06-03 |
2005-02-24 |
Cell Genesys, Inc. |
Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
|
WO2005000891A2
(en)
*
|
2003-06-26 |
2005-01-06 |
Merck Patent Gmbh |
Thrombopoietin proteins with improved properties
|
US20050059023A1
(en)
*
|
2003-09-16 |
2005-03-17 |
Cantor Thomas L. |
Methods and kits for monitoring resistance to therapeutic agents
|
US7211559B2
(en)
*
|
2003-10-31 |
2007-05-01 |
University Of Maryland, Baltimore |
Factor VIII compositions and methods
|
WO2005055930A2
(en)
*
|
2003-12-03 |
2005-06-23 |
University Of Rochester |
Recombinant factor viii having increased specific activity
|
SI1750733T1
(sl)
*
|
2004-05-03 |
2014-03-31 |
Emory University |
POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B
|
WO2005123928A1
(en)
*
|
2004-06-08 |
2005-12-29 |
Battelle Memorial Institute |
Production of human coagulation factor viii from plant cells and whole plants
|
EP1824988B1
(en)
*
|
2004-11-12 |
2017-04-19 |
Bayer HealthCare LLC |
Site-directed modification of fviii
|
US20100256062A1
(en)
*
|
2004-12-06 |
2010-10-07 |
Howard Tommy E |
Allelic Variants of Human Factor VIII
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
EP1968999A2
(en)
|
2005-12-07 |
2008-09-17 |
Technische Universität München |
Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
WO2007115724A2
(en)
*
|
2006-04-11 |
2007-10-18 |
Csl Behring Gmbh |
Method of increasing the in vivo recovery of therapeutic polypeptides
|
US7939632B2
(en)
*
|
2006-06-14 |
2011-05-10 |
Csl Behring Gmbh |
Proteolytically cleavable fusion proteins with high molar specific activity
|
WO2008077616A1
(en)
*
|
2006-12-22 |
2008-07-03 |
Csl Behring Gmbh |
Modified coagulation factors with prolonged in vivo half-life
|
EP1935430A1
(en)
*
|
2006-12-22 |
2008-06-25 |
CSL Behring GmbH |
Modified coagulation factors with prolonged in vivo half-life
|
FR2913020B1
(fr)
*
|
2007-02-23 |
2012-11-23 |
Biomethodes |
Nouveaux facteurs viii pour le traitement des hemophiles de type a
|
EP1988101A1
(en)
|
2007-05-04 |
2008-11-05 |
Novo Nordisk A/S |
Improvement of factor VIII polypeptide titers in cell cultures
|
US8183345B2
(en)
|
2007-11-01 |
2012-05-22 |
University Of Rochester |
Recombinant factor VIII having reduced inactivation by activated protein C
|
EP2149603A1
(en)
|
2008-07-28 |
2010-02-03 |
DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH |
Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
|
EP2393828B1
(en)
|
2009-02-03 |
2016-10-12 |
Amunix Operating Inc. |
Extended recombinant polypeptides and compositions comprising same
|
ES2966234T3
(es)
|
2009-06-09 |
2024-04-18 |
Prolong Pharmaceuticals Llc |
Composiciones de hemoglobina
|
EP2470670A4
(en)
|
2009-08-24 |
2013-07-10 |
Amunix Operating Inc |
COAGULATION FACTOR VII COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREOF
|
EP2498803A4
(en)
*
|
2009-11-13 |
2013-05-15 |
Puget Sound Blood Ct |
FACTOR VIII IMMUNOGENICITY T LYMPHOCYTE T EPOXY VARIANTS
|
PL2506868T3
(pl)
|
2009-12-06 |
2018-06-29 |
Bioverativ Therapeutics Inc. |
Chimeryczne i hybrydowe polipeptydy czynnika krzepnięcia viii-fc oraz sposoby ich stosowania
|
EP2524054A2
(en)
*
|
2010-01-14 |
2012-11-21 |
Haplomics, Inc. |
Predicting and reducing alloimmunogenicity of protein therapeutics
|
AU2011274423B2
(en)
|
2010-07-09 |
2016-02-11 |
Bioverativ Therapeutics Inc. |
Chimeric clotting factors
|
WO2012006623A1
(en)
|
2010-07-09 |
2012-01-12 |
Biogen Idec Hemophilia Inc. |
Systems for factor viii processing and methods thereof
|
EP2635297B1
(en)
*
|
2010-11-05 |
2019-02-27 |
Baxalta GmbH |
A new variant of antihemophilic factor viii having increased specific activity
|
MX2013007551A
(es)
*
|
2011-01-05 |
2013-10-30 |
Expression Therapeutics Llc |
Metodo y sistema para suspension de cultivo celular.
|
PT2717898T
(pt)
|
2011-06-10 |
2019-05-20 |
Bioverativ Therapeutics Inc |
Compostos pró-coagulantes e processos para a sua utilização
|
PL3513804T3
(pl)
|
2011-07-08 |
2022-07-11 |
Bioverativ Therapeutics Inc. |
Chimeryczne i hybrydowe polipeptydy czynnika VIII i sposoby ich stosowania
|
EP2737311B1
(en)
|
2011-07-25 |
2020-12-02 |
Bioverativ Therapeutics Inc. |
Assays to monitor bleeding disorders
|
CN102277379B
(zh)
*
|
2011-08-18 |
2013-07-24 |
中国科学院遗传与发育生物学研究所 |
表达凝血因子viii的表达载体及其应用
|
BR112014017111A8
(pt)
|
2012-01-12 |
2018-05-15 |
Biogen Idec Inc |
métodos de redução de imunogenicidade contra o fator viii em indivíduos submetidos à terapia de fator viii
|
EP2804623B1
(en)
|
2012-01-12 |
2019-08-07 |
Bioverativ Therapeutics Inc. |
Chimeric factor viii polypeptides and uses thereof
|
HUE060629T2
(hu)
|
2012-02-15 |
2023-03-28 |
Bioverativ Therapeutics Inc |
VIII. faktor készítmények és eljárások elõállításukra és alkalmazásukra
|
HUE043537T2
(hu)
|
2012-02-15 |
2019-08-28 |
Bioverativ Therapeutics Inc |
Rekombináns VIII faktor fehérjék
|
EP2666782A1
(en)
*
|
2012-05-22 |
2013-11-27 |
Imnate Sarl |
Coagulation factor VIII with reduced immunogenicity.
|
WO2013185113A1
(en)
|
2012-06-08 |
2013-12-12 |
Biogen Idec Ma Inc. |
Procoagulant compounds
|
CA2875247A1
(en)
|
2012-06-08 |
2013-12-12 |
Biogen Idec Ma Inc. |
Chimeric clotting factors
|
EP2870250B2
(en)
|
2012-07-06 |
2022-06-29 |
Bioverativ Therapeutics Inc. |
Cell line expressing single chain factor viii polypeptides and uses thereof
|
US10138291B2
(en)
|
2012-07-11 |
2018-11-27 |
Bioverativ Therapeutics Inc. |
Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
|
EP3970738A1
(en)
|
2012-07-25 |
2022-03-23 |
Bioverativ Therapeutics Inc. |
Blood factor monitoring assay and uses thereof
|
CA2888806A1
(en)
|
2012-10-18 |
2014-04-24 |
Biogen Idec Ma Inc. |
Methods of using a fixed dose of a clotting factor
|
EP2914293A4
(en)
|
2012-10-30 |
2016-04-20 |
Biogen Ma Inc |
METHOD OF USE OF FVIII POLYPEPTIDE
|
US10272163B2
(en)
|
2012-12-07 |
2019-04-30 |
The Regents Of The University Of California |
Factor VIII mutation repair and tolerance induction
|
HUE053136T2
(hu)
|
2013-02-15 |
2021-06-28 |
Bioverativ Therapeutics Inc |
Optimizált VIII. faktor gén
|
EA037906B1
(ru)
|
2013-03-15 |
2021-06-04 |
Биовератив Терапьютикс Инк. |
Препараты полипептида фактора ix
|
HUE047933T2
(hu)
|
2013-03-15 |
2020-05-28 |
Bioverativ Therapeutics Inc |
Faktor VIII polipeptid készítmények
|
WO2015021423A2
(en)
|
2013-08-08 |
2015-02-12 |
Biogen Idec Ma Inc. |
Purification of chimeric fviii molecules
|
EP3033097B1
(en)
|
2013-08-14 |
2021-03-10 |
Bioverativ Therapeutics Inc. |
Factor viii-xten fusions and uses thereof
|
CA2928314A1
(en)
|
2013-10-22 |
2015-04-30 |
Dbv Technologies |
Method of treating haemophilia by inducing tolerance to blood factors
|
EP3065769A4
(en)
|
2013-11-08 |
2017-05-31 |
Biogen MA Inc. |
Procoagulant fusion compound
|
WO2015085276A1
(en)
|
2013-12-06 |
2015-06-11 |
Biogen Idec Ma Inc. |
Population pharmacokinetics tools and uses thereof
|
EP2881463A1
(en)
|
2013-12-09 |
2015-06-10 |
DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH |
Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
|
HRP20220960T1
(hr)
|
2014-01-10 |
2022-10-28 |
Bioverativ Therapeutics Inc. |
Kimerni proteini faktora viii i njihova upotreba
|
NZ722391A
(en)
|
2014-02-04 |
2022-12-23 |
Biogen Ma Inc |
Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
|
WO2015127129A1
(en)
*
|
2014-02-19 |
2015-08-27 |
Bloodworks |
Factor viii b cell epitope variants having reduced immunogenicity
|
EP3114138B1
(en)
|
2014-03-05 |
2021-11-17 |
Pfizer Inc. |
Improved muteins of clotting factor viii
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
JP6909203B2
(ja)
|
2015-08-03 |
2021-07-28 |
バイオベラティブ セラピューティクス インコーポレイテッド |
第ix因子融合タンパク質及びそれらの製造方法及び使用方法
|
PE20231949A1
(es)
*
|
2015-10-30 |
2023-12-05 |
Spark Therapeutics Inc |
VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
|
TW202229555A
(zh)
|
2015-11-13 |
2022-08-01 |
日商武田藥品工業股份有限公司 |
用於a型血友病基因治療之編碼表現增加之重組fviii變異體之病毒載體
|
KR102484553B1
(ko)
|
2015-11-13 |
2023-01-04 |
다케다 야쿠힌 고교 가부시키가이샤 |
A형 혈우병의 유전자 요법을 위한 증가된 발현을 갖는 재조합 fviii 변이체를 인코딩하는 바이러스 벡터
|
CN109072214B
(zh)
|
2016-02-01 |
2023-02-17 |
比奥贝拉蒂治疗公司 |
优化的因子viii基因
|
US11046749B2
(en)
|
2016-06-24 |
2021-06-29 |
Mogam Institute For Biomedical Research |
Chimera protein comprising FVIII and vWF factors, and use thereof
|
IL308416A
(en)
|
2016-12-02 |
2024-01-01 |
Bioverativ Therapeutics Inc |
Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
|
MA46968A
(fr)
|
2016-12-02 |
2019-10-09 |
Bioverativ Therapeutics Inc |
Procédés d'induction de tolérance immunitaire à des facteurs de coagulation
|
EP3622065A1
(en)
|
2017-05-09 |
2020-03-18 |
Emory University |
Clotting factor variants and their use
|
JP7374883B2
(ja)
|
2017-08-09 |
2023-11-07 |
バイオベラティブ セラピューティクス インコーポレイテッド |
核酸分子およびその使用
|
US20210038744A1
(en)
|
2018-02-01 |
2021-02-11 |
Bioverativ Therapeutics Inc. |
Use of lentiviral vectors expressing factor viii
|
RU2020136050A
(ru)
|
2018-04-04 |
2022-05-06 |
Сайджилон Терапьютикс, Инк. |
Имплантируемые частицы и соответствующие способы
|
SG11202010767SA
(en)
|
2018-05-18 |
2020-11-27 |
Bioverativ Therapeutics Inc |
Methods of treating hemophilia a
|
KR20210034013A
(ko)
|
2018-07-16 |
2021-03-29 |
박스알타 인코퍼레이티드 |
발현이 증가된 재조합 fviii 변이체들을 인코딩하는 바이러스 벡터를 이용한 혈우병의 유전적 치료법
|
KR20210042128A
(ko)
|
2018-08-09 |
2021-04-16 |
바이오버라티브 테라퓨틱스 인크. |
핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도
|
UY38389A
(es)
|
2018-09-27 |
2020-04-30 |
Sigilon Therapeutics Inc |
Dispositivos implantables para terapia celular y métodos relacionados
|
TW202039546A
(zh)
|
2019-01-16 |
2020-11-01 |
美商巴克斯歐塔公司 |
用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
|
KR20220024628A
(ko)
|
2019-06-19 |
2022-03-03 |
바이오버라티브 테라퓨틱스 인크. |
혈우병 및 낮은 골 무기질 밀도를 치료하기 위한 재조합 인자 viii-fc
|
WO2020257586A2
(en)
|
2019-06-20 |
2020-12-24 |
Baxalta Incorporated |
Method of treatment with viral-based gene therapy
|
WO2021119357A2
(en)
|
2019-12-12 |
2021-06-17 |
Baxalta Incorporated |
Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
|
TW202246505A
(zh)
*
|
2021-03-05 |
2022-12-01 |
俄羅斯聯邦商亞那拜恩有限公司 |
編碼凝血因子ix蛋白的密碼子優化的核酸及其用途
|
JP2024514307A
(ja)
*
|
2021-03-31 |
2024-04-01 |
ヘモネティクス・コーポレーション |
血液凝固測定装置の品質管理配合物
|
CN117858895A
(zh)
|
2021-06-14 |
2024-04-09 |
武田药品工业株式会社 |
使用表达增强的编码重组fviii变体的病毒载体的血友病a基因疗法
|
CN117836319A
(zh)
|
2021-08-23 |
2024-04-05 |
比奥维拉迪维治疗股份有限公司 |
优化的因子viii基因
|
CA3232988A1
(en)
|
2021-09-30 |
2023-04-06 |
Bioverativ Therapeutics Inc. |
Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
|
WO2024081309A1
(en)
|
2022-10-11 |
2024-04-18 |
Sigilon Therapeutics, Inc. |
Engineered cells and implantable elements for treatment of disease
|